Psychiatry Research Unit and Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Mol Psychiatry. 2023 Apr;28(4):1667-1678. doi: 10.1038/s41380-023-01955-x. Epub 2023 Jan 23.
Bipolar-disorder's pathophysiology and the mechanism by which medications exert their beneficial effect is yet unknown, but others' and our data implicate patients' brain mitochondrial-dysfunction and its amendment by mood-stabilizers. We recently designed a novel mouse bipolar-disorder-like model using chronic administration of a low-dose of the oxidative-phosphorylation complex I inhibitor, rotenone. Four and eight weeks rotenone treatment induced manic- and depressive-like behavior, respectively, accompanied by mood-related neurochemical changes. Here we aimed to investigate whether each of the autophagy-enhancers lithium (a mood-stabilizer), trehalose and resveratrol and/or each of the reactive oxygen species (ROS)-scavengers, resveratrol and N-acetylcystein and/or the combinations lithium+resveratrol or trehalose+N-acetylcystein, can ameliorate behavioral and neurochemical consequences of neuronal mild mitochondrial-dysfunction. We observed that lithium, trehalose and N-acetylcystein reversed rotenone-induced manic-like behavior as well as deviations in protein levels of mitochondrial complexes and the autophagy marker LC3-II. This raises the possibility that mild mitochondrial-dysfunction accompanied by impaired autophagy and a very mild increase in ROS levels are related to predisposition to manic-like behavior. On the other hand, although, as expected, most of the drugs tested eliminated the eight weeks rotenone-induced increase in protein levels of all hippocampal mitochondrial complexes, only lithium ubiquitously ameliorated the depressive-like behaviors. We cautiously deduce that aberrant autophagy and/or elevated ROS levels are not involved in predisposition to the depressive phase of bipolar-like behavior. Rather, that amending the depressive-like characteristics requires different mitochondria-related interventions. The latter might be antagonizing N-methyl-D-aspartate receptors (NMDARs), thus protecting from disruption of mitochondrial calcium homeostasis and its detrimental consequences. In conclusion, our findings suggest that by-and-large, among the autophagy-enhancers and ROS-scavengers tested, lithium is the most effective in counteracting rotenone-induced changes. Trehalose and N-acetylcystein may also be effective in attenuating manic-like behavior.
双相障碍的病理生理学以及药物发挥其有益作用的机制尚不清楚,但我们和其他人的数据表明,患者的大脑线粒体功能障碍及其通过情绪稳定剂的修正与双相障碍有关。我们最近使用低剂量的氧化磷酸化复合物 I 抑制剂鱼藤酮对慢性给药设计了一种新型的小鼠双相障碍样模型。4 周和 8 周的鱼藤酮治疗分别诱导了躁狂样和抑郁样行为,同时伴有与情绪相关的神经化学变化。在这里,我们旨在研究每种自噬增强剂(锂,一种情绪稳定剂)、海藻糖和白藜芦醇以及/或每种活性氧(ROS)清除剂,白藜芦醇和 N-乙酰半胱氨酸和/或锂+白藜芦醇或海藻糖+N-乙酰半胱氨酸的组合是否可以改善神经元轻度线粒体功能障碍的行为和神经化学后果。我们观察到锂、海藻糖和 N-乙酰半胱氨酸逆转了鱼藤酮诱导的躁狂样行为以及线粒体复合物和自噬标志物 LC3-II 的蛋白水平偏差。这表明轻度线粒体功能障碍伴随着自噬受损和 ROS 水平的非常轻微升高与躁狂样行为的易感性有关。另一方面,尽管正如预期的那样,测试的大多数药物消除了所有海马体线粒体复合物的 8 周鱼藤酮诱导的蛋白水平升高,但只有锂普遍改善了抑郁样行为。我们谨慎地推断,异常的自噬和/或升高的 ROS 水平与双相障碍样行为的抑郁阶段的易感性无关。相反,纠正抑郁样特征需要不同的与线粒体相关的干预措施。后者可能是拮抗 N-甲基-D-天冬氨酸受体(NMDARs),从而防止线粒体钙稳态的破坏及其不利后果。总之,我们的研究结果表明,在所测试的自噬增强剂和 ROS 清除剂中,锂在对抗鱼藤酮诱导的变化方面基本上最为有效。海藻糖和 N-乙酰半胱氨酸也可能有效减轻躁狂样行为。